ALS MyMatch Request for Applications of Investigational Product Candidates
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital is seeking applications of experimental therapies for inclusion in our newest initiative, ALS MyMatch. This is a patient-centered, efficient approach for screening investigational products in early-phase biomarker driven (Phase 1b/2a) clinical trials in ALS across several experienced trial-ready enrolling centers.
In addition to evaluating safety and tolerability each ALS MyMatch trial design will be customized to answer specific scientific questions of interest relevant to the applicant’s investigational product. The best fit for primary scientific scope of a MyMatch clinical trial includes biological efficacy, target engagement, CNS penetrance, pharmacokinetics and/or dose finding trials.
This program is not for Phase 1 healthy volunteer studies.
Please consider applying to the HEALEY ALS Platform Trial if the primary objective is a clinical efficacy trial in ALS.
Learn more about the ALS MyMatch Trial
We encourage applications for investigational products from the academic and industry community to be considered for inclusion in ALS MyMatch in 2025. The first 2-3 selected applicants will receive partial funding support from the Healey & AMG Center.
Timeline for Submission
Release Date: Friday April 4, 2025
Informational Webinar: Thursday, April 10, 2025 05:00 PM EDT
Application Due Date: Friday, May 16, 2025
Review Criteria
- Relevance of target to human disease
- Pre-clinical data to support target and therapy
- Clinical trial readiness (availability of compound and placebo (if applicable), and regulatory approval status)
- Availability of relevant biomarkers for participant selection as well as target engagement
Informational Webinar
This informational webinar is for stakeholders developing therapies in ALS.
We invite company representatives and academic investigators with therapies in development for ALS to register and participate in an upcoming informational webinar on Thursday, April 10, 2025, at 05:00 PM Eastern Time, to learn about ALS MyMatch and the therapy application process.
Please contact us at healeyamgcenterforals@mgh.harvard.edu for all inquiries.
*Note: Announcement of a public webinar for ALS patients and families on MyMatch is forthcoming.
Confidential Disclosure Agreements (CDAs)
Confidential Disclosure Agreements (CDAs) are executed between MGH (on behalf of the Review Committee members) and the institution or company before the ALS MyMatch Trial Therapy Application Form is submitted.
Download the CDA template (Word document) and submit completed CDA form to healeyamgcenterforals@mgh.harvard.edu.
ALS MyMatch Application
Download the application form (PDF) and submit your completed application and CDA to healeyamgcenterforals@mgh.harvard.edu.